Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Part of paid clinical trials in La Jolla, California.

Sponsor
Hatim Husain
Study ID
NCT04043195
Phase
PHASE1/PHASE2
Status
Active Not Recruiting

Conditions

  • Advanced NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
  • Oxaliplatin — DRUG
    65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
  • Ipilimumab — DRUG
    1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles

Study Details

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system).

Key Dates

Start date
Aug 14, 2019
Status verified
May 2025
Primary completion
Dec 31, 2025
Completion
Dec 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab + Oxaliplatin + Ipilimumab
    Cohort 1

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: 4 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
UC San Diego Moores Cancer CenterLa JollaCalifornia92093-

Find similar trials in La Jolla, CA

By research site
UC San Diego Moores Cancer Center· La Jolla, CA

Related Studies